Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (2016 - 2025)

ImmunityBio (IBRX) has disclosed Shares Outstanding for 13 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 18.63% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 18.63% year-over-year, with the annual reading at $1.0 billion for FY2025, 18.63% up from the prior year.
  • Shares Outstanding for Q4 2025 was $1.0 billion at ImmunityBio, up from $985.0 million in the prior quarter.
  • The five-year high for Shares Outstanding was $1.0 billion in Q4 2025, with the low at $383.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $604.2 million, with a median of $554.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 1.47% in 2022, then surged 66.8% in 2023.
  • Over 5 years, Shares Outstanding stood at $397.8 million in 2021, then increased by 5.97% to $421.6 million in 2022, then skyrocketed by 59.14% to $670.9 million in 2023, then grew by 27.13% to $852.9 million in 2024, then rose by 18.63% to $1.0 billion in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $1.0 billion, $985.0 million, and $915.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.